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Abstract
OBJECTIVES: There is very little evidence comparing the safety and efficacy of alcohol septal ablation versus septal myectomy for a septal
reduction in patients with hypertrophic obstructive cardiomyopathy. This study aimed to compare the immediate and long-term out-
comes of these procedures.
METHODS: Following propensity score matching, we retrospectively analysed outcomes in 105 patients who underwent myectomy and
105 who underwent septal ablation between 2011 and 2017 at 2 reference centres.
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RESULTS: The mean age was 51.9 ± 14.3 and 52.2 ± 14.3 years in the myectomy and ablation groups, respectively (P = 0.855), and postoper-
ative left ventricular outflow tract gradients were 13 (10–19) mmHg vs 16 (12–26) mmHg; P = 0.025. The 1-year prevalence of the New
York Heart Association class III–IV was higher in the ablation group (none vs 6.4%; P = 0.041). The 5-year overall survival rate [96.8% (86.3–
99.3) after myectomy and 93.5% (85.9–97.1) after ablation; P = 0.103] and cumulative incidence of sudden cardiac death [0% and 1.9%
(0.5–7.5), respectively P = 0.797] did not differ between the groups. The cumulative reoperation rate within 5 years was lower after myec-
tomy than after ablation [2.0% (0.5–7.6) vs 14.6% (8.6–24.1); P = 0.003]. Ablation was associated with a higher reoperation risk (subdistribu-
tional hazard ratio = 5.9; 95% confidence interval 1.3–26.3, P = 0.020). At follow-up, left ventricular outflow tract gradient [16 (11–20) vs 23
(15–59) mmHg; P < 0.001] and prevalence of 2+ mitral regurgitation (1.1% vs 10.6%; P = 0.016) were lower after myectomy than after
ablation.
CONCLUSIONS: Both procedures improved functional capacity; however, myectomy better-resolved classes III–IV of heart failure. Septal
ablation was associated with higher reoperation rates. Myectomy demonstrated benefits in gradient relief and mitral regurgitation elimina-
tion. The results suggest that decreasing rates of myectomy procedures need to be investigated and reconsidered.
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LVOT Left ventricular outflow tract
MR Mitral regurgitation
NYHA New York Heart Association
SAM Systolic anterior motion
SHR Subdistributional hazard ratio
SM Septal myectomy
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a common genetic car-
diovascular disease with a 1 in 500 prevalence in the general
population [1] with a global burden in at least 122 countries with
populations exceeding 500 000 [2]. HCM involves symptoms of
chronic heart failure, with some patients complaining of palpita-
tions and/or chest pain at rest or during exertion; however, most
people are asymptomatic [3]. In the absence of randomized trials
[4], initial drug therapy with non-vasodilating b-blockers, diso-
pyramide, or verapamil is usually administered to reduce the left
ventricular outflow tract (LVOT) obstruction and improve func-
tional capacity. If patients are in the New York Heart Association
(NYHA) functional class III–IV with an LVOT gradient >50 mmHg
despite maximum tolerable medical therapy, invasive septal re-
duction therapy is indicated [1, 3]. Previously, the standard surgi-
cal procedure for HCM was septal myectomy (SM) (Morrow
procedure). According to a recent review, SM offers better LVOT
gradient resolution [5] than alcohol septal ablation (ASA).
Nevertheless, the SM procedure is disappearing in Western coun-
tries, giving way to less invasive procedures. In North America,
the annual rate of SM decreased by 24.5% between 2003 and
2011, and the rate of ASA increased by 56.2% [6]. Although ASA
was introduced more than 20 years ago as a feasible alternative
to SM, there are still no randomized trials comparing SM and
ASA. When researchers compare SM and ASA in a non-
randomized study, selection bias is always present. Thus, we
aimed to compare the long-term outcomes of SM and ASA in 2
reference centres and used propensity score matching to identify
groups with similar background covariates that need to be
controlled.
PATIENTS AND METHODS
In this retrospective database study involving propensity score
analysis, we investigated 345 consecutive patients who under-
went SM for obstructive HCM at Meshalkin National Research
Center and 150 consecutive patients who underwent ASA at
Sverdlovsk Regional Hospital #1 between 2011 and 2017. The
present study was conducted in compliance with the Declaration
of Helsinki. All patients received optimal preoperative medical
therapy comprising non-vasodilating b-blockers and/or calcium-
channel blockers. The inclusion criteria were as follows: age
>_18 years, interventricular septum (IVS) thickness >_15 mm (on
echocardiography) and instantaneous peak Doppler LVOT pres-
sure gradient >_50 mmHg. This retrospective study was approved
by the Institutional Review Board on 6 November 2018 (88.3-PP-
19); the need for obtaining individual patient consent was waived
because of the retrospective nature of the study.
After 1:1 propensity score matching, the study cohort included
105 patients in each group (Fig. 1). The primary endpoint was
overall survival. The secondary endpoints were cumulative reop-
eration or reintervention rate, residual and recurrent LVOT gradi-
ent, residual mitral regurgitation (MR), rate of permanent
pacemaker implantation, functional capacity 1 year after the pro-
cedure, and cumulative incidence of sudden cardiac death.
Patient follow-up examinations were scheduled at 6 and
12 months postoperatively, and annually thereafter. The last
follow-up was performed by phone in March 2019.
SURGICAL PROCEDURES
Surgical septal myectomy
The aorta was cross-clamped, and a cold crystalloid cardioplegic
solution (CustodiolV
R
HTK Solution; Dr. Franz Ko¨hler Chemie
GmbH, Alsbach-Ha¨hnlein, Germany) provided myocardial pro-
tection with an antegrade root flow. A transverse aortotomy ex-
posed the septum. Transaortic extended myectomy was
performed in all cases using the operative technique previously
described by Morrow and modified by Messmer [7, 8]. When
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grafting or surgical ablation for atrial fibrillation. To assess resid-
ual MR, systolic anterior motion (SAM) syndrome and LVOT ob-
struction after surgery, intraoperative transoesophageal
echocardiography was used.
Alcohol septal ablation
The ASA technique is described in the Supplementary Material.
Briefly, the tightness of the balloon occlusion was assessed by
injecting dye into the septal branch. Intraoperative transoesopha-
geal echocardiography was performed to evaluate the perfusion
zone of the target septal perforator. The gradient had to be re-
duced by at least 50% during the ‘occlusive test’ for ablation.
When this was achieved, 3 ml of ethanol was infused slowly for
3–5 min. Then, the balloon was flushed with contrast dye.
Ethanol was applied for 5 min. On achieving the target haemody-
namic effect, the procedure was terminated. When necessary,
ASA was combined with percutaneous coronary intervention or
catheter ablation for atrial fibrillation before/after ASA.
Statistical analysis
Statistical analysis was performed using STATA version 13.0
(StataCorp LP, College Station, TX, USA). The Shapiro–Wilk test
was used to test the normality of continuous variables.
Continuous data were presented as mean ± standard deviation
for variables with normal distribution and median (25–75th per-
centile) for variables with non-normal distribution. Categorical
data were described as absolute numbers and relative
frequencies. Before propensity score matching, the 2 groups
were compared using the independent samples t-test (normal
distribution) or the Kolmogorov–Smirnov 2-sample test (non-
normal distribution) for continuous variables, and Pearson’s v2
test with an (N-1)/N correction factor for categorical variables.
After propensity score matching, between-group differences
were compared using the paired t-test or the Wilcoxon signed-
rank test for continuous variables, and McNemar’s test for cate-
gorical variables. Using multiple logistic regression analysis, a
propensity score was calculated for each patient, defined as the
probability that the patient received SM. The baseline variables
included in the propensity score analysis are listed in Table 1. The
nearest neighbour approach, without replacement, and 5-to-1
digit-matching was used to identify 1:1 matched patients (Caliper
0.1). The balance between variables before and after matching
was assessed in terms of percentage standardized bias (reported
as a percentage). The Kaplan–Meier method was used to evaluate
overall survival, and results were presented with 95% confidence
intervals (95% CIs). Survival curves were compared using a strati-
fied log-rank test for matched pairs. Baseline variables, including
age, sex, NYHA class III–IV, moderate or severe MR, left ventricu-
lar ejection fraction, IVS thickness and LVOT gradient were evalu-
ated to identify the predictors of a high LVOT gradient (>50
mmHg) after ASA, and multivariable analysis was performed us-
ing logistic regression models. Risks of sudden cardiac death and
reintervention were analysed using a competing risk proportional
hazard model (Fine and Gray method). The inclusion criterion for
the full regression model was P <_ 0.200 or clinical significance,
and the limit for stepwise backwards elimination was P < 0.100.
The results of the competing risk regression analysis were
Figure 1: Patient enrolment flowchart. AF: atrial fibrillation; ASA: alcohol septal ablation; CABG: coronary artery bypass grafting; HCM: hypertrophic cardiomyopathy;
PCI: percutaneous coronary intervention; PSM: propensity score matching; SM: septal myectomy.
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expressed as subdistribution hazard ratios (SHRs), with respective
95% CIs. A P-value of <0.05 was considered statistically
significant.
RESULTS
Before propensity score matching
Baseline demographic and echocardiographic data are presented
in Table 1. Before propensity score matching, SM was related to
older age (55.0 ± 13.4 vs 50.7 ± 14.6 years), NYHA class III–IV
(64.3% vs 47.3%), moderate or severe MR (73.9% vs 24.0%),
higher instantaneous peak Doppler LVOT pressure gradient [83
(interquartile range, IQR 70–96) mmHg vs 57 (IQR 38–84)
mmHg] and thicker IVS [24 (IQR 22–27) mm vs 22 (IQR 19–26)
mm]. The ASA group had a significantly lower proportion of
patients with atrial fibrillation (5.3% vs 19.4%) and coronary ar-
tery disease (13.3% vs 30.4%).
The non-matched groups (ASA vs SM) did not differ in terms of
hospital mortality rate (0% vs 1.7%; P= 0.104) and incidence of per-
manent pacemaker implantation during the early postoperative pe-
riod (12.0% vs 10.1%; P= 0.540). There were 5 (1.4%) and 4 (2.7%)
early complications (P= 0.352) that required intervention/surgery in
SM and ASA groups, respectively. Iatrogenic ventricle septal defects
(n= 3, 0.9%) and left ventricular free wall ruptures (n= 2, 0.6%) were
successfully treated intraoperatively in the SM cohort. In ASA co-
hort, right coronary artery thrombosis, requiring percutaneous in-
tervention (n= 1, 0.7%), the left main dissection, requiring bypass
grafting (n= 1, 0.7%) and femoral pseudoaneurysm, requiring early
surgical intervention (n= 2, 1.3%), were observed. The non-matched
groups (ASA vs SM) did not differ in terms of 5-year overall survival
[93.6% (95% CI 87.6–96.8%) vs 96.5% (95% CI 93.6–98.2%); log-rank
test P= 0.712; Supplementary Material, Fig. S1], or cumulative inci-
dence of sudden cardiac death within 5 years (0% vs 1.4%; 95% CI
0.3–5.3%; log-rank test P= 0.337; Supplementary Material, Fig. S2).
SM was neither associated with all-cause mortality [hazard ratio,
HR = 1.15 (95% CI 0.2–2.5); P= 0.713] nor sudden cardiac death
[SHR = 1.9 (95% CI 0.2–17.8); P= 0.570].
Residual LVOT pressure gradient measured by transthoracic
echocardiography before discharge was significantly higher in
the ASA group than in the SM group [16 (IQR 12–26) mmHg vs
14 (IQR 11–19) mmHg; P = 0.004]. Nevertheless, there were 21
(14.0%) and 4 (1.2%) patients in the ASA and SM groups
(P < 0.001), respectively, who underwent reoperation. Cumulative
reoperation rates within 5 years were 1.2% (95% CI 0.4–3.1%) and
15.3% (95% CI 10.1–22.9%) in the SM and ASA groups, respec-
tively (P < 0.001, Supplementary Material, Fig. S3). Therefore, ASA
was associated with significantly higher reoperation rates, with
an SHR of 9.3 (95% CI 2.5–35.0, P = 0.001, Supplementary
Material, Table S1).
After propensity score matching
Baseline characteristics with minimal standardized bias in the
2 propensity score-matched groups are presented in Table 2.
The mean age (51.9 ± 14.3 vs 52.2 ± 14.3 years, P = 0.855), the
proportion of NYHA class III–IV (53.3% vs 54.3%, P = 0.891),
rate of moderate or severe SAM-mediated MR (33.3% vs
34.3%, P = 0.855), LVOT gradient [78 (IQR 63–90) vs 72 (IQR
48–90) mmHg, P = 0.642] and IVS thickness [23 (IQR 21–26) vs
23 (IQR 20–27) mm, P = 0.630] did not differ between the SM
and ASA groups.
Early outcomes. There were no in-hospital deaths after ASA,
while 1 patient (1.0%) died after SM due to myocardial infarction
(P = 1.000). Nine (8.6%) patients in the SM group required perma-
nent pacemaker implantation postoperatively, including 8 (7.6%)
with complete atrioventricular block and 1 (1.0%) with sinus
node dysfunction after surgical ablation for atrial fibrillation.
There were 10 (9.5%) patients with complete atrioventricular
blocks after ASA, and there were no differences in the need for
permanent pacemaker implantation between matched groups
(P = 1.000).
In general, both SM and ASA resulted in significant decreases in
LVOT pressure gradient and MR severity between presurgery and
discharge. Nevertheless, SM demonstrated benefits in SAM-
mediated MR elimination: only 1 (1.0%) patient had residual mod-
erate MR, and there were no patients with residual severe MR af-
ter surgery. However, 12 (11.4%) patients in the ASA group were
discharged with residual MR (P = 0.006), including 1 patient (1.0%)
Table 1: Baseline characteristics of septal myectomy and alcohol septal ablation groups before propensity score matching
Covariates before matching SM (n = 345) ASA (n = 150) Bias (%) P-value
Age (years) 55.0 ± 13.4 50.7 ± 14.6 30.7 0.001
Male, n (%) 155 (44.9) 72 (48.0) -6.1 0.529
PM/ICD, n (%) 9 (2.6) 3 (2.0) 4.0 0.686
NYHA class III–IV, n (%) 222 (64.3) 71 (47.3) 36.6 <0.001
AF, n (%) 67 (19.4) 8 (5.3) 43.7 <0.001
AH, n (%) 206 (59.7) 81 (54.0) 12.7 0.193
CAD, n (%) 105 (30.4) 20 (13.3) 41.5 <0.001
DM, n (%) 33 (9.6) 7 (4.7) 19.1 0.066
MR 2+, n (%) 255 (73.9) 36 (24.0) 115.0 <0.001
LVEF (%) 71.1 ± 8.2 70.9 ± 8.0 2.9 0.769
PG (mmHg) 83 (70–96) 57 (38–84) 48.8 <0.001
IVS (mm) 24 (22–27) 22 (19–26) 39.4 <0.001
AF: atrial fibrillation; AH: arterial hypertension; ASA: alcohol septal ablation; CAD: coronary artery disease; DM: diabetes mellitus; ICD: implantable cardioverter-
defibrillator; IVS: interventricular septum; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; NYHA: New York Heart Association; PG: instantaneous
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with severe MR (P = 1.000). Furthermore, the LVOT gradient after
SM was lower than that after ASA [13 (IQR 10–19) mmHg vs 16
(IQR 12–26) mmHg; P = 0.025]. Only 1 (1.0%) and 7 (6.7%) patients
in the SM and ASA groups, respectively, had residual LVOT ob-
struction with a pressure gradient >50 mmHg (P = 0.077) at dis-
charge. The ASA group multivariable logistic regression analyses
identified the preoperative LVOT gradient as the only factor asso-
ciated with residual LVOT gradient >50 mmHg after ASA with
odds ratio 1.03 (95% CI 1.01–1.05, P = 0.018, Supplementary
Material, Table S2). In these cases, non-vasodilating b-blockers, ti-
trated to a maximum tolerated dose, were administrated to re-
duce heart failure symptoms and improve functional capacity,
and dynamic evaluation was selected over reoperation.
Follow-up data. The follow-up was complete (clinical follow-
up or death) in 97.1% of patients. The mean follow-up duration
was 61.8 ± 36.2 months. Four and 12 deaths occurred in SM and
ASA groups, respectively. In the SM group, 2 deaths occurred af-
ter thromboembolism complications, and sudden cardiac death
occurred in 2 cases (6 and 7 years after SM). Causes of late death
in the ASA cohort were sudden cardiac arrest (n = 3), myocardial
infarction (n = 2), thromboembolic complications (n = 2), non-
cardiac complications (n = 2) and unknown (n = 3). The 5-year
overall survival rates were 96.8% (95% CI 86.3–99.3%) and 93.5
(95% CI 85.9–97.1%; P = 0.103, Fig. 2) and cumulative incidence
of sudden cardiac death within 5 years was 0% and 1.9% (95% CI
0.5–7.5%; P = 0.797, Fig. 3) in the SM and ASA groups, respec-
tively. The HR for risk of death was 1.8 (95% CI 0.5–5.7; P = 0.353)
and SHR for the competing risk of sudden cardiac death after
ASA was 0.8 (95% CI 0.1–8.5; P = 0.868).
Both procedures improved functional capacity; however, the
prevalence of NYHA class III–IV among survived matched patients
was significantly higher in the ASA group 1 year postoperatively [6
(6.4%) vs 0 (0%); P = 0.041]. The overall incidence of new-onset
atrial fibrillation among survived matched patients was 6 (6.4%)
and 9 (9.6%) in the SM and ASA groups, respectively (P = 0.606).
Significantly more ASA patients required reoperation
(Supplementary Material, Table S3; 14.3% vs 1.9%; P = 0.004).
Cumulative reoperation rates within 5 years were 2.0% (95%
CI 0.5–7.6%) and 14.6% (95% CI 8.6–24.1%) in SM and ASA
groups, respectively (P = 0.003, Fig. 4). Competing-risks regres-
sion analysis (Supplementary Material, Table S4) confirmed
that ASA was associated with reintervention (SHR = 5.9; 95% CI
1.3–26.3, P = 0.020).
Echocardiographic follow-up results were available in 86% of
patients (87 SM, 94 ASA). Therefore, 81 matched pairs were ana-
lysed. Residual LVOT gradients after SM and ASA were 16 (IQR
11–20) and 23 (IQR 15–59) mmHg, respectively (P < 0.001). At the
last follow-up, there was a significantly higher rate of residual
LVOT gradient >30 mmHg in the ASA group (5.7% vs 40.4%;
P < 0.001). The rate of LVOT obstruction (>50 mmHg) was higher
in the ASA group (27.7% vs 1.1%, P < 0.001). There were higher
rates of residual SAM-mediated MR grade 2 or greater in the
ASA group (10.6% vs 1.1%; P = 0.016).
DISCUSSION
The main finding of our study was that freedom from reopera-
tion and LVOT gradient relief was superior after SM; although,
Figure 2: Overall survival in propensity score-matched groups (SM vs ASA).
ASA: alcohol septal ablation; CI: confidence interval; SM: septal myectomy.
Table 2: Baseline characteristics of septal myectomy and al-
cohol septal ablation groups after propensity score matching
Covariates SM (n = 105) ASA (n = 105) Bias (%) P-value
Age (years) 51.9 ± 14.3 52.2 ± 14.3 -2.7 0.855
Male, n (%) 57 (54.3) 55 (52.4) 3.8 0.783
PM/ICD, n (%) 1 (1.0) 2 (1.9) -8.0 0.563
NYHA class III–IV, n (%) 56 (53.3) 57 (54.3) -2.0 0.891
AF, n (%) 7 (6.7) 5 (4.8) 8.2 0.554
AH, n (%) 56 (53.3) 58 (55.2) -3.9 0.783
CAD, n (%) 25 (23.8) 20 (19.1) 10.4 0.403
DM, n (%) 8 (7.6) 5 (4.8) 9.7 0.393
MR 2+, n (%) 35 (33.3) 36 (34.3) -2.2 0.885
LVEF (%) 70.6 ± 7.4 70.8 ± 8.3 -3.6 0.787
PG (mmHg) 78 (63–90) 72 (48–90) 4.8 0.642
IVS (mm) 23 (21–26) 23 (20–27) 7.7 0.630
AF: atrial fibrillation; AH: arterial hypertension; ASA: alcohol septal ablation;
CAD: coronary artery disease; DM: diabetes mellitus; ICD: implantable
cardioverter-defibrillator; IVS: interventricular septum; LVEF: left ventricular
ejection fraction; MR: mitral regurgitation; NYHA: New York Heart
Association; PG: instantaneous peak Doppler left ventricular outflow tract
pressure gradient; PM: pacemaker; SM: septal myectomy.
Figure 3: Cumulative incidence of sudden cardiac death within 5 years in
propensity score-matched groups (SM vs ASA). ASA: alcohol septal ablation; CI:
confidence interval; SCD: sudden cardiac death; SM: septal myectomy.
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overall survival and freedom from sudden cardiac death did not
differ between groups. Functional capacity, in terms of NYHA
class improvement, favoured SM 1 year after treatment.
Survival
Whether ASA or SM is more beneficial for long-term survival
remains unclear. Previously, Noseworthy et al. [9] detected an in-
creased risk of life-tethering ventricular arrhythmias in patients
with a high residual gradient after ASA. Additionally, in a large
international multicentre cohort study, Vriesendorp et al. [10]
concluded that sudden cardiac death risk was significantly
higher after ASA (HR = 2.1) than after SM. According to ten Cate
et al. [11], ASA was also an independent predictor of cardiac
death and aborted sudden cardiac death for ventricular tachy-
cardia/fibrillation (unadjusted HR = 5.2, propensity-score ad-
justed HR = 6.1). Nevertheless, a recently published systematic
review and meta-analysis [5, 12], conducted on retrospective co-
hort studies, found similarly low rates of long-term mortality. A
single-centre study from Mayo Clinic reported that SM was as-
sociated with a significant survival benefit compared with ASA
among unadjusted patients [13]. The difference was explained by
the fact that unadjusted ASA patients were older and more likely
to have comorbidities. After propensity matching, there was no
significant difference in overall survival. However, patients in the
SM group in our study were older with comorbidities.
Additionally, our cohort was relatively young compared to the
Mayo group (52 vs 65 years). We did not find benefits in survival
rate or sudden cardiac death rate in either the unadjusted or
matched groups. Steggerda et al. [14] found that overall survival
after ASA and SM was comparable, and age was the only inde-
pendent predictor of all-cause mortality. Considering the low
event rates after both SM and ASA, an adequately powered ran-
domized trial comparing the long-term benefits of SM and ASA
is never feasible [15]. Thus, future prospective non-randomized
studies accessing long-term outcomes would be a good
alternative.
Permanent pacemaker implantation
The main non-fatal complication after septal reduction therapy
was a complete atrioventricular blockage. According to a US na-
tionwide inpatient database [6], the need for permanent pace-
maker insertion after SM was 9.8%, and it varied based on
hospital volume (8.9–13.8%; P < 0.001). However, undergoing
ASA in a lower-volume centre was not associated with worse
outcomes (pacemaker implantation) compared with that of high-
volume centres (11.5%). In our study, events occurred in 8.6–
9.5% of patients, which is consistent with the in-hospital rate of
pacemaker implantation after SM and ASA in high-volume (ter-
tiary) hospitals. Findings from the Poon et al. [5] systematic re-
view showed that ASA was associated with an increased
likelihood of permanent pacemaker implantation (odds ratio 3.1,
P < 0.001) and varied between 2.4% and 12.5% in SM and 1.7–
22.0% in ASA. A Dutch meta-analysis [12] also emphasized that
patients had more than twice the risk of pacemaker implantation
after ASA (10.0%; 95% CI 7.8–12.1%) compared to that after SM
(4.4; 95% CI 2.6–6.2%; P < 0.001). Authors from the Mayo Clinic
[13] recently reported a four-fold higher rate of permanent pace-
maker implantation after ASA (17.4%) compared with that after
SM (3.9%). The authors suggested that lower risk of pacemaker
insertion after SM reflects the surgical experience and is possible
in other dedicated HCM centres. In our study, ASA was not asso-
ciated with higher atrioventricular-block risk requiring pace-
maker implantation. We suspect that this due to the learning
curve for SM. The pacemaker implantation rate after SM in our
practice has decreased significantly over the years to 3.1% [16].
The risk of pacemaker implantation should be taken into consid-
eration at the time of the selection of optimal septal reduction
therapies.
Gradient relief
In this study, both SM and ASA were considered effective and
resulted in significant LVOT gradient reduction post-procedure.
This was consistent with the results of Liebregts et al. [12]. We ob-
served significantly higher postoperative LVOT pressure gradients
after ASA compared to that after SM. Steggerda et al. [14]
reported post-procedure LVOT gradients of 12 (8–20) mmHg af-
ter SM and 10 (0–20) mmHg after ASA (P < 0.001); however, they
emphasized that gradients were evaluated using different modali-
ties, the invasive measurement for ASA and transoesophageal
echocardiography for SM, and therefore, such comparisons were
not applicable. Nevertheless, during follow-up, resting and pro-
voked echocardiographic gradients were higher after ASA than
SM. Our findings are consistent with the propensity score-
matched study by Nguyen et al. [13], where more complete
LVOT gradient relief was observed after SM. Moreover, authors
found that the early follow-up gradient in ASA patients was
strongly related to preoperative gradients and suggested that
ASA may not adequately relieve LVOT obstruction in patients
with high (>40 mmHg) preoperative resting LVOT gradient [13].
We also demonstrated the relationship between baseline LVOT
gradient and residual LVOT gradient (>50 mmHg) after ASA.
Nevertheless, there were no significant differences in residual
LVOT obstruction with >50 mmHg gradient between groups at
discharge. The high residual gradient is regarded as a failure of
the initial procedure and is a clear indication for reintervention
in patients with residual symptoms. Both a recent systematic
Figure 4: Cumulative incidence of reoperation within 5 years in propensity
score-matched groups of patients stratified according to the choice of septal
reduction therapy (SM vs ASA). ASA: alcohol septal ablation; CI: confidence in-
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review [5] of the Mayo Clinic data [13] and our study have
reported a more complete LVOT gradient resolution following
SM. We found that during follow-up, residual LVOT gradient in-
creased from 21.4 (18.4–24.3) mmHg to 42.2 (35.5–48.0) mmHg
after ASA, and the number of patients with LVOT obstruction
>50 mmHg increased from 6.7% to 27.7%. However, there were
no negative trends in haemodynamic results after SM. Despite
the immediate LVOT gradient and symptom relief obtained after
ASA, high LVOT gradients may recur long-term. This should be
considered when initial therapy is selected. Moreover, Quintana
et al. [17] revealed that patients who undergo SM following a
previously unsuccessful ASA are at an increased risk of preopera-
tive diastolic dysfunction and arrhythmias and postoperative
complete heart block.
Reoperation
In their meta-analysis comparing 16 SM cohorts and 11 ASA
cohorts, Liebregts et al. [12] reported a higher need for reinter-
vention after ASA (7.7%) compared to that after SM (1.6%)
(P = 0.001). One limitation of this analysis was that SM patients
were treated earlier than 1990 (13 out of 16 studies), and ASA
patients were treated after 1990 (9 out of 11 studies). A system-
atic search conducted by Poon et al. [5] based on the best evi-
dence articles published in the last 2 decades also found that the
rate of reintervention was significantly higher following ASA. An
updated meta-analysis by Osman et al. [18] (including 40 obser-
vational studies comparing long-term outcomes of ASA and SM)
reported that the need for reoperation was significantly higher
after ASA (11.6% vs 1.5%; P < 0.001).
Although at least 3 previously published systematic reviews
and meta-analyses confirmed evidence that SM provides more
durable results in terms of a lower need for repeat septal reduc-
tion, all studies had limitations, such as inherently different base-
line characteristics in SM and ASA cohorts, analyses conducted
on cohort data instead of individual patient data, and differing
enrolment periods. Therefore, the interpretation of these results
must be undertaken with caution.
Since the last systematic reviews and meta-analyses were pub-
lished [18], only one study has reported long-term outcomes af-
ter SM and ASA [13]. This study was unique for several reasons. It
was the first analysis based on a relatively large prospectively
maintained database with propensity score matching to identify
ASA and SM groups with similar preoperative characteristics.
They observed overall reinterventions rates of 1.0% after SM and
35.0% after ASA (HR = 33.3). This finding is consistent with our re-
port, with a 1.9% reoperation rate after SM and 14.3% after ASA
(HR = 7.0). Most patients in the Nguyen et al. [13] study under-
went SM after failed ASA, while in our series, most patients
underwent ASA again after unsuccessful ASA. This discrepancy
may be explained by referral bias. In the Nguyen et al. [13]
single-centre study, patients were referred to the same clinic for
SM after failed ASA, and that may have already provided more
durable outcomes. However, in our 2 centre study, most patients,
after unsuccessful ASA, were not referred for SM given that a
dedicated SM centre was 1500 km far. In fact, in our study, all
consecutive patients referred to Meshalkin Center during the
study period were scheduled for SM, whereas all consecutive
patients referred to Sverdlovsk Hospital underwent ASA.
Therefore, in contrast to the results reported by Nguyen et al.
[13], our results are more likely to be limited by referral, rather
than by selection bias.
Finally, it is important to note that patients with failed ASA, re-
ferred for SM, may have an increased risk of cardiac death, ad-
vanced heart failure, and implantable cardioverter-defibrillator
discharges. This supports SM as the preferred treatment option
for septal reduction [17].
Limitations
The present study had several limitations. Although data were
collected prospectively, our findings were limited by confound-
ing factors and bias associated with retrospective studies. In addi-
tion, our study was limited by a relatively small sample size after
matching; therefore, the study may be underpowered to detect
differences in primary and secondary clinical outcomes. Using
the propensity score analysis, we sought to minimize the effects
of these factors. Propensity score matching restricts the SM co-
hort to ASA patients with similar baseline data; therefore, the co-
hort may not represent typical SM/ASA patients. Finally, our
cohort may not be representative one because of national, selec-
tion and referral biases.
CONCLUSION
The findings of our analysis suggest that SM eliminates LVOT ob-
struction and SAM-mediated MR more effectively, as well as pro-
viding longer freedom from reoperation in HCM patients.
Additionally, ASA is associated with higher reoperation rates. Our
findings suggest that the disappearance of SM needs to be inves-
tigated due to its benefits over ablation.
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